| 证券代码：603976 | 证券简称：正川股份 | 公告编号：2023-057 | | --- | --- | --- | | 债券代码：113624 | 债券简称：正川转债 | | 重庆正川医药包装材料股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2、2023 年 6 月 21 日为公司 2022 年度利润分配的除息日，"正川转债"的 转股价格调整为 46.32 元/股，具体内容请详见公司于 2023 年 6 月 15 日披露的 《关于权益分派引起的"正川转债"转股价格调整的公告》（公告编号：2023-035）。 二、可转债本次转股情况 一、可转债发行上市概况 （一）可转债发行情况 经中国证券监督管理委员会证监许可[2021]198号《关于核准重庆正川医药 包装材料股份有限公司公开发行可转换公司债券的批复》核准，重庆正川医药 包装材料股份有限公司（以下简称"公司"）于2021年4月28日公开发行可转换 公司债券405万张，每张面值100元人民币，本次发行可转换 ...

| 证券代码：603976 | 证券简称：正川股份 | 公告编号：2023-056 | | --- | --- | --- | | 债券代码：113624 | 债券简称：正川转债 | | 重庆正川医药包装材料股份有限公司 关于使用部分闲置募集资金进行现金管理到期赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重庆正川医药包装材料股份有限公司（以下简称"公司"）于2022年7月1日 召开了第三届董事会第二十一次会议、第三届监事会第十八次会议，审议通过了 《关于使用部分闲置募集资金进行现金管理的议案》，同意公司及子公司使用额 度不超过人民币10,000万元的闲置募集资金进行现金管理，以上资金额度在董事 会审议通过之日起12个月内可以循环滚动使用。公司于2023年6月30日召开了第 四届董事会第七次会议、第四届监事会第五次会议，再次审议通过了《关于使用 部分闲置募集资金进行现金管理的议案》，同意公司及子公司使用额度不超过人 民币6,000万元的闲置募集资金进行现金管理，以上资金额度在董事会审议通过 之日起12个月内可以循 ...

重庆正川医药包装材料股份有限公司 关于为全资子公司银行贷款提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 证券代码：603976 | 证券简称：正川股份 | 公告编号：2023-055 | | --- | --- | --- | | 债券代码：113624 | 债券简称：正川转债 | | 一、担保情况概述 （一）本次担保的基本情况 公司全资子公司正川永成因日常生产经营发展需要，向中国工商银行股份有 限公司重庆北碚支行（以下简称"工商银行"）申请人民币 3,000 万元借款，借 款期限为 1 年。2023 年 9 月 6 日，公司和工商银行签订《最高额保证合同》，为 正川永成与工商银行签订的《流动资金借款合同》提供连带责任保证担保。本担 保事项无反担保。 （二）本次担保履行的内部决策程序 1 被担保人名称：重庆正川医药包装材料股份有限公司（以下简称"公司"） 之全资子公司重庆正川永成医药材料有限公司（以下简称"正川永成"）。 本次担保金额及已实际为其提供的担保余额：公司本次为全资子公司正 ...

| 证券代码：603976 | 证券简称：正川股份 | 公告编号：2023-054 | | --- | --- | --- | | 债券代码：113624 | 债券简称：正川转债 | | 重庆正川医药包装材料股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 9 月 1 日(星期五)至 9 月 7 日(星期四)16:00 前登录上证 路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zczq@cqzcjt.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 重庆正川医药包装材料股份有限公司（以下简称"公司"）已于 2023 年 8 月 25 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 半年度经营成果、财务状况，公司计划于 2023 年 9 月 8 日上午 10:00-11:0 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥447,675,217.15, representing a 9.08% increase compared to ¥410,426,279.38 in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2023 was ¥30,562,154.91, a decrease of 24.58% from ¥40,521,108.84 in the previous year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥22,376,850.23, down 38.05% from ¥36,123,306.46 in the same period last year[18]. - Basic earnings per share for the first half of 2023 were ¥0.20, a decrease of 25.93% from ¥0.27 in the same period last year[19]. - The weighted average return on net assets for the first half of 2023 was 2.55%, down 0.89 percentage points from 3.44% in the previous year[19]. - The total operating revenue for the first half of 2023 reached ¥447,675,217.15, an increase of 9.5% compared to ¥410,426,279.38 in the same period of 2022[127]. - The total operating costs amounted to ¥419,950,870.93, up from ¥365,308,912.00, reflecting a year-over-year increase of 14.9%[127]. - The company's operating profit for the first half of 2023 was CNY 34,730,235.32, down from CNY 45,930,471.75 in the same period of 2022, representing a decrease of 24.2%[128]. - The total comprehensive income for the first half of 2023 was CNY 30,562,154.91, compared to CNY 40,521,108.84 in the first half of 2022, reflecting a decline of 24.6%[133]. Cash Flow and Financial Position - The net cash flow from operating activities increased significantly to ¥48,917,411.74, a 319.18% rise from ¥11,669,836.10 in the previous year[18]. - The company's cash and cash equivalents were reported at ¥207,186,940.17 as of June 30, 2023, a decrease from ¥212,432,533.40 at the end of 2022[119]. - The total cash and cash equivalents at the end of the period stood at ¥74,995,210.76, an increase from ¥14,490,772.77 at the end of the first half of 2022[138]. - The cash inflow from operating activities was CNY 461,705,692.91, an increase from CNY 420,046,431.53 in the first half of 2022[134]. - The cash outflow from operating activities was CNY 412,788,281.17, slightly up from CNY 408,376,595.43 in the same period last year[134]. - The company reported a net cash flow from financing activities of -¥12,061,835.18, compared to -¥48,676,446.71 in the previous year, indicating a reduction in cash outflow[138]. - The company's total liabilities amounted to ¥832,782,878.81 as of June 30, 2023, with current liabilities at ¥394,539,203.74 and non-current liabilities at ¥438,243,675.07[115]. Assets and Investments - The total assets at the end of the reporting period were ¥2,038,484,263.93, reflecting a 1.54% increase from ¥2,007,660,704.19 at the end of the previous year[18]. - The company's fixed assets increased to ¥799,861,344.00 as of June 30, 2023, compared to ¥710,427,637.04 at the end of 2022[120]. - The total assets of the company reached ¥2,038,484,263.93 as of June 30, 2023, compared to ¥2,007,660,704.19 at the end of 2022[120]. - The total amount of unconverted bonds is RMB 404,906,000, representing 99.9768% of the total issued convertible bonds[112]. - The company reported a total of ¥182,581,639.07 in trading financial assets as of June 30, 2023, an increase from ¥159,059,321.55 at the end of 2022[119]. Research and Development - The company has established itself as a leading enterprise in the pharmaceutical glass packaging industry, focusing on the production of borosilicate glass containers and caps, with over 700 clients including major pharmaceutical groups[29]. - The company has upgraded its sodium-calcium glass furnace, enhancing its market position in the sodium-calcium glass container segment[27]. - The company has developed a full-scale production capability for borosilicate glass tubes and injection vials, supporting customized client needs and future growth[27]. - The company is focusing on optimizing its technology center and enhancing its R&D capabilities in glass tube and bottle production[33]. - The company holds 46 patents, including 5 invention patents, reflecting its commitment to research and development in pharmaceutical glass packaging[30]. Market Position and Strategy - The company is actively expanding into the medical beauty product packaging market, establishing partnerships with leading companies in the sector[29]. - The company has formed deep strategic partnerships with well-known pharmaceutical companies, enhancing its market presence and competitiveness[26]. - The company has a strong brand presence, with its "Zhengchuan" trademark recognized as a famous brand in Chongqing, contributing to its competitive advantage[28]. - The company is positioned to benefit from the increasing quality demands in the pharmaceutical packaging industry, as lower-quality competitors exit the market[25]. - The company has accelerated the production of pre-filled syringes and improved the quality of borosilicate glass tubes, aiming to capture market opportunities in the next 2-3 years[32]. Environmental Compliance - The company has established a robust environmental management system and is classified as a key pollutant discharge unit, ensuring compliance with environmental standards[55]. - The company reported a chemical oxygen demand (COD) level of 61 mg/L, significantly below the standard limit of 100 mg/L, indicating compliance with environmental regulations[56]. - The biochemical oxygen demand (BOD) was recorded at 13.6 mg/L, well under the permissible limit of 20 mg/L, demonstrating effective waste management practices[56]. - The company has established a wastewater treatment facility and operates dust removal and denitrification systems, which are functioning well and ensuring pollutant discharge meets standards[58]. - The company has received environmental protection approval for multiple projects, including the automation of pharmaceutical glass bottle cleaning and inspection, indicating ongoing commitment to sustainable practices[59]. Risks and Challenges - The company faces potential policy risks as national standards for pharmaceutical packaging materials may be raised to align with those in developed countries, impacting production processes and costs[44]. - The company is heavily reliant on the pharmaceutical industry, and any slowdown in this sector could directly affect demand for its packaging materials, posing a market risk[45]. - The company’s main products are pharmaceutical glass packaging materials, which may face substitution risks from new materials developed in the industry[46]. - There is a risk that fundraising investment projects may not achieve expected returns due to market changes or policy shifts, impacting future profitability[47]. - The company’s performance is significantly affected by fluctuations in raw material and energy prices, which could impact overall financial results[48]. Corporate Governance - The actual controllers of the company have pledged not to interfere in the company's management activities or infringe on its interests[74]. - The controlling shareholder, Zhengchuan Investment, has promised not to engage in any business that competes with the company during the relevant period[77]. - The company will ensure that any necessary related party transactions are conducted fairly and in accordance with market rules[80]. - The company has stated that there are currently no non-operating fund occupations by controlling shareholders or related parties[83]. - The company has no changes in controlling shareholders or actual controllers during the reporting period[104]. Accounting Policies - The financial statements are prepared based on the principle of going concern, with no significant doubts regarding the company's ability to continue operations in the next 12 months[159]. - The company adheres to the accounting standards, ensuring that the financial statements accurately reflect its financial position and operating results[161]. - The company confirms that its cash and cash equivalents are highly liquid investments that are easily convertible to known amounts of cash[167]. - The company applies simplified measurement methods for trade receivables and contract assets without significant financing components, recognizing expected credit losses over the entire lifetime[176]. - The company recognizes contract assets based on the relationship between performance obligations and customer payments, presenting them net after offsetting with contract liabilities[184].

独立董事关于第四届董事会第十次会议的相关独立意见 我们依据中国证监会《关于在上市公司建立独立董事制度的指导意见》等 有关规定，基于独立判断的立场，对公司召开的第四届董事会第十次会议审议 的相关事项进行了认真的审议，并发表以下独立意见： 一、关于 2023 年半年度募集资金存放与实际使用情况的专项报告的独立董 事意见 公司 2023 年半年度募集资金存放与实际使用情况符合中国证监会、上海证 券交易所对上市公司募集资金存放与使用的相关规定，不存在变相改变募集资金 用途和损害股东利益的情况，不存在募集资金存放和使用违规的情形。 公司编制的《2023 年半年度募集资金存放与实际使用情况的专项报告》真 实反映了公司 2023 年半年度募集资金存放与实际使用情况，内容真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏。 综上，我们同意《2023 年半年度募集资金存放与实际使用情况的专项报告》。 （以下无正文） (本页无正文,仅为重庆正川医药包装材料股份有限公司独立董事关于第四届 董事会第十次会议的相关独立意见签字页) (本页无正文,仅为重庆正川医药包装材料股份有限公司独立董事关于第四届 董事会第十次会议的相关独立意 ...

| 证券代码：603976 | 证券简称：正川股份 | 公告编号：2023-053 | | --- | --- | --- | | 债券代码：113624 | 债券简称：正川转债 | | 重庆正川医药包装材料股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、募集资金管理情况 （一）募集资金管理情况 为规范募集资金的管理和使用，保护投资者的权益，根据相关法律法规及公 司《募集资金管理办法》等相关规定，公司及募投项目实施主体重庆正川永成医 1 药材料有限公司连同保荐机构申万宏源证券承销保荐有限责任公司于 2021 年 5 月 17 日与重庆银行股份有限公司北碚支行签订了《募集资金专户存储三方监管 协议》，明确了各方的权利和义务。以上三方监管协议与上海证券交易所《募集 资金专户存储三方监管协议（范本）》不存在重大差异。报告期内，公司严格按 照上述监管协议的规定使用募集资金。 （二）《募集资金专户存储三方监管协议》的履行情况及存在的问题 截至 2023 年 6 月 ...

| | | 重庆正川医药包装材料股份有限公司 第四届董事会第九次会议决议公告 重庆正川医药包装材料股份有限公司（以下简称"公司"）于 2023 年 8 月 11 日以电子邮件或电话等形式向各位董事发出了召开第四届董事会第九次会议 的通知。会议于 2023 年 8 月 18 日以现场结合通讯方式在正川永成研发楼三楼会 议室召开，应参加董事 9 名，实际参加董事 9 名。 本次会议由董事长邓勇先生召集和主持。会议的召集、召开和表决程序均符 合《公司法》等法律、行政法规以及《公司章程》《公司董事会议事规则》的有 关规定，会议的召集、召开合法有效。 二、董事会会议审议情况 1、会议审议通过了《关于不向下修正"正川转债"转股价格的议案》 公司本次不向下修正"正川转债"转股价格，同时在未来六个月内（即 2023 年 8 月 19 日至 2024 年 2 月 18 日），如再次触发"正川转债"转股价格向下修正 条款，亦不提出向下修正方案。自 2024 年 2 月 19 日起首个交易日重新开始计算， 若再次触发"正川转债"转股价格向下修正条款，届时董事会将再次召开会议决 定是否行使"正川转债"的转股价格向下修正权利。 本公司 ...

| 证券代码：603976 | 证券简称：正川股份 | 公告编号：2023-050 | | --- | --- | --- | | 债券代码：113624 | 债券简称：正川转债 | | 重要内容提示： 自2023年7月31日至2023年8月18日，重庆正川医药包装材料股份有限公司 （以下简称"公司"）股票已出现连续三十个交易日中至少有十五个交易日的收 盘价低于当期转股价格的90%之情形，触发"正川转债"转股价格向下修正条款。 经公司第四届董事会第九次会议审议，公司董事会决定本次不向下修正"正 川转债"转股价格，同时在未来六个月内（即2023年8月19日至2024年2月18日）， 如再次触发"正川转债"转股价格向下修正条款，亦不提出向下修正方案。自 2024年2月19日起首个交易日重新开始计算，若再次触发"正川转债"转股价格 向下修正条款，届时董事会将再次召开会议决定是否行使"正川转债"的转股价 格向下修正权利。 一、可转债基本情况 经中国证券监督管理委员会证监许可[2021]198 号《关于核准重庆正川医药 包装材料股份有限公司公开发行可转换公司债券的批复》核准，公司于 2021 年 4 月 28 日公开发 ...

| | | 重庆正川医药包装材料股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 在不影响公司日常经营活动，确保资金安全性、流动性的前提下，对公司闲 置自有资金进行现金管理，进一步提高资金使用效率，增加公司和股东收益。 重要内容提示： 现金管理产品提供方：渝农商理财有限责任公司（以下简称"渝农商理 财"）； 现金管理产品名称：渝农商理财益尊封闭式2023年第32008期； 现金管理金额：共计5,000万元； 现金管理期限：99天； 履行的审议程序：公司于2023年6月30日召开了第四届董事会第七次会议、 第四届监事会第五次会议，审议通过了《关于使用闲置自有资金进行现金管理的 议案》，同意公司使用额度不超过人民币25,000万元的闲置自有资金进行现金管 理，以上资金额度在董事会审议通过之日起12个月内可以循环滚动使用。 一、本次现金管理概况 （一）目的 （二）资金来源 本次现金管理的资金全部来源于闲置自有资金。 （三）现金管理产品的基本情况 | 产品提 | 产品类型 | 产 ...